Cholangiocarcinoma Non Resectable clinical trials

Explore recruiting cholangiocarcinoma non resectable clinical trials.

Recruiting cholangiocarcinoma non resectable studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cholangiocarcinoma Non Resectable trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Trans-arterial treatment of patients with intra-hepatic cholangiocarcinoma not amenable to resection (TOMCAT)

Norway

Therapeutic use (Phase IV) EU CTIS Study details

IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

GEMOXIA02: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cholangiocarcinoma Non Resectable trials by city

Cholangiocarcinoma Non Resectable in Toronto Cholangiocarcinoma Non Resectable in Vancouver Cholangiocarcinoma Non Resectable in Montreal Cholangiocarcinoma Non Resectable in Calgary Cholangiocarcinoma Non Resectable in Edmonton Cholangiocarcinoma Non Resectable in Ottawa Cholangiocarcinoma Non Resectable in Winnipeg Cholangiocarcinoma Non Resectable in Quebec City Cholangiocarcinoma Non Resectable in Hamilton Cholangiocarcinoma Non Resectable in Kitchener Cholangiocarcinoma Non Resectable in London Cholangiocarcinoma Non Resectable in Halifax Cholangiocarcinoma Non Resectable in New York Cholangiocarcinoma Non Resectable in Los Angeles Cholangiocarcinoma Non Resectable in Chicago Cholangiocarcinoma Non Resectable in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease